Continuous subcutaneous terbutaline infusion for treatment of preterm labor
Record ID 32011001323
English
Authors' recommendations:
Terbutaline is used for the prevention of preterm birth. Typically, treatment for women with preterm uterine contractions is started with intensive tocolytic therapy. When contractions have been reduced to fewer than 4 to 6 per hour, terbutaline is administered as a continuous subcutaneous infusion to prevent the reinstatement of premature labor and preterm birth. Depending on the treatment protocol, terbutaline is infused with a pump at 0.05 mg to 0.75 mg per hour with boluses of 0.25 mg at regular intervals or as needed. Average duration of infusion ranges from 4 weeks to 7 weeks; however, some patients may require more than 10 weeks of infusion.
Details
Project Status:
Completed
Year Published:
2011
URL for published report:
http://www.hayesinc.com/hayes/crd/?crd=11058
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Humans
- Infusions, Subcutaneous
- Obstetric Labor, Premature
- Pregnancy
- Terbutaline
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
2011 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.